Press Release
Source: Viral Genetics, Inc.

Dutton Associates Announces Investment Opinion: Viral Genetics Initial Rating At Speculative Buy By Dutton Associates

Azusa, California; October 10, 2006

Dutton Associates initiates coverage of Viral Genetics VRAL with a Speculative Buy rating and a price target of $.20. The 13-page report by Dutton senior analyst William R. Prather, RPh, MD is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.

We believe Viral Genetics, Inc.'s common stock should appreciate on milestone announcements. We believe the Company is nearing the announcement of filing a new drug application (NDA) in South Africa as well as initiating clinical trials in the U.S. for its anti-HIV therapeutic, VGV-1. It is a drug discovery and development Company developing products based on its Thymus Nuclear Protein (TNP) compound aimed primarily at the treatment of infectious diseases and focusing on HIV and AIDS. Viral Genetics also has a research interest in autoimmune diseases, cancer and immunological deficiencies. Because the compound is early in its development, we believe an investment in Viral Genetics is suitable only for patient, speculative, risk-tolerant investors. We are assigning the common stock of the Company a rating of Speculative Buy with a 12-month price target of $0.20 based on the value of comparable companies in Phase 1 or early development of their products.

About Dutton Associates

Dutton Associates is one of the largest independent investment research firms in the U.S. Its 31 senior analysts are primarily CFAs and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.

The cost of enrollment in our one-year continuing research program is US $39,500 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. The Firm does not accept any equity compensation. We received $35,000 from the Company for 4 quarterly Research Reports with coverage commencing on 10/10/2006. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.

Contact Information: Dutton Associates John M. Dutton, 916-941-8119

About Viral Genetics
Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV and AIDS using its thymus nuclear protein compound. This compound may have other potential applications for other infectious, autoimmune, and immunological deficiency diseases that the company intends to study in the future.  Viral Genetics believes that VGV-1 represents a significant and unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment.  Online at www.viralgenetics.com

For additional information, please contact Kirsten Ayars at 805-452-7909.   For investor inquiries, please contact Evan Pondel at 310-279-5973.

This news release contains forward-looking statements that involve risks and uncertainties associated with clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports filed with the SEC. VGV-1 is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of VGV-1 in the treatment of any disease or health condition and the development of studies and strategies leading to commercialization of VGV-1 in the United States. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.

Source: Viral Genetics, Inc.

Click here to return to our Press Release selection page.

Press Releases

Media Kits

Media Inquiries

News Subscription Service